share_log

Pfizer | CORRESP: CORRESP

Pfizer | CORRESP: CORRESP

輝瑞 | CORRESP:信函
美股SEC公告 ·  08/22 23:58

牛牛AI助理已提取核心訊息

Pfizer Inc. has submitted a letter to the Securities and Exchange Commission (SEC) on August 22, 2024, in response to the SEC's comments on its previously filed Tender Offer Statement. The SEC's comments, dated August 15, 2024, pertained to Pfizer's Schedule TO-I filed on August 12, 2024. Pfizer has concurrently filed Amendment No. 1 to the Schedule TO, incorporating revisions based on the SEC's feedback. The SEC had raised concerns regarding Pfizer's right to exclude certain colleagues from participating in the Modification Offer based on jurisdictional legal restrictions, as well as the eligibility criteria for participants, which initially included only individuals actively employed since no later than July 24, 2024. Pfizer acknowledged the SEC's comments and made the necessary revisions to its Summary Term Sheet to ensure compliance with Rule 13e-4(f)(8)(i) and the Global Exemptive Order dated March 21, 2001. The correspondence was facilitated by Marc S. Gerber of Skadden, Arps, Slate, Meagher & Flom LLP, with copies sent to Pfizer executives David M. Denton and Margaret M. Madden.
Pfizer Inc. has submitted a letter to the Securities and Exchange Commission (SEC) on August 22, 2024, in response to the SEC's comments on its previously filed Tender Offer Statement. The SEC's comments, dated August 15, 2024, pertained to Pfizer's Schedule TO-I filed on August 12, 2024. Pfizer has concurrently filed Amendment No. 1 to the Schedule TO, incorporating revisions based on the SEC's feedback. The SEC had raised concerns regarding Pfizer's right to exclude certain colleagues from participating in the Modification Offer based on jurisdictional legal restrictions, as well as the eligibility criteria for participants, which initially included only individuals actively employed since no later than July 24, 2024. Pfizer acknowledged the SEC's comments and made the necessary revisions to its Summary Term Sheet to ensure compliance with Rule 13e-4(f)(8)(i) and the Global Exemptive Order dated March 21, 2001. The correspondence was facilitated by Marc S. Gerber of Skadden, Arps, Slate, Meagher & Flom LLP, with copies sent to Pfizer executives David M. Denton and Margaret M. Madden.
輝瑞公司於2024年8月22日向證券交易委員會(SEC)提交了一封回覆SEC關於其先前提交的要約收購報表的意見的函件。SEC的意見日期爲2024年8月15日,涉及輝瑞於2024年8月12日提交的TO-I表格。輝瑞同時提交了關於TO表格的修正稿第1號,根據SEC的反饋進行了修訂。SEC提出的擔憂涉及輝瑞有權根據司法法律限制排除某些同事參與修改要約的問題,以及參與者的資格標準,最初只包括自2024年7月24日之前一直在職的個人。輝瑞承認了SEC的意見,並對其摘要條款表進行了必要的修訂,以確保符合2001年3月21日頒佈的第13e-4(f)(8)(i)規則和全球豁免令。此函件由Skadden, Arps, Slate, Meagher & Flom LLP的Marc S. Gerber協助,抄送給了輝瑞的高管David m. Denton和Margaret m. Madden。
輝瑞公司於2024年8月22日向證券交易委員會(SEC)提交了一封回覆SEC關於其先前提交的要約收購報表的意見的函件。SEC的意見日期爲2024年8月15日,涉及輝瑞於2024年8月12日提交的TO-I表格。輝瑞同時提交了關於TO表格的修正稿第1號,根據SEC的反饋進行了修訂。SEC提出的擔憂涉及輝瑞有權根據司法法律限制排除某些同事參與修改要約的問題,以及參與者的資格標準,最初只包括自2024年7月24日之前一直在職的個人。輝瑞承認了SEC的意見,並對其摘要條款表進行了必要的修訂,以確保符合2001年3月21日頒佈的第13e-4(f)(8)(i)規則和全球豁免令。此函件由Skadden, Arps, Slate, Meagher & Flom LLP的Marc S. Gerber協助,抄送給了輝瑞的高管David m. Denton和Margaret m. Madden。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。